



INFERSCIENCE

# Risk Adjustment in 2027:

What's **Changing** and What to Do **Now**

**Subbu Ramalingam & Michael Lesnik**

Industry Experts & Leadership Team

VBCExhibitHall  
.com



*Educational Webinar Series*

[www.inferscience.com](http://www.inferscience.com)

# Your Speakers Today



**Subbu Ramalingam**

Healthcare Industry Leader & Expert  
Board of Advisors, Inferscience



**Michael Lesnik**

VP of Provider Sales, Inferscience  
15-Year Healthcare IT Expert

# About InferScience



**Dr. Sunil Nihalani**

Founder & Practicing Physician

**Clinical Impact:** Focused on **improving real-world clinical workflows** and reducing provider burden.

**Proven Experience:** **10+ years** advancing risk adjustment accuracy across value-based care organizations.

**National Reach:** Supporting risk and quality programs for **2M+ patient lives nationwide**.

**Smart Technology:** EHR-embedded AI delivering real-time, **encounter-linked HCC** and quality insights at the point of care.

**Core Pillars:** Improving **documentation integrity, RAF accuracy,** and audit readiness.

# What You Will Walk Away With Today



**The 2027 Rate Notice: Key Changes** and the market forces driving them



**CY 2027 Final Rule: Strategic implications** for your risk adjustment model



**Documentation Tightening:** Why retrospective strategies are **losing ground**



**HCC Coding Strategies:** Navigating the **four paths to risk management** in 2027



**"Getting It Right":** Lessons from **10 years** and **2M+ lives**

# What the 2027 CMS Rate Notice Actually Means

## NET RATE INCREASE

**+2.48%**

Advance notice proposed +0.09% - entire swing drive by CMS retaining 2024 risk adjustment model

## DOLLAR IMPACT

**\$13B+**

Above 2026 Levels

## EFFECTIVE GROWTH RATE

**5.33%**

Revised upward from 4.97% driven by the inclusion of Original Medicare program experience data through Q4 2025

## CODING PATTERN ADJUSTMENT

**5.9%**

Held at statutory minimum, sustained downward pressure on effective risk scores continues

## STRATEGIC IMPLICATIONS

The favorable rate reflects a model decision, not a shift in CMS's direction on risk adjustment oversight. The coding adjustment signals that pressure on coding accuracy continues regardless of the rate outcome. **CMS was explicit that future model updates remain on the agenda.** Organizations should use this window to strengthen encounter-based documentation practices.

# Unlinked Chart Review Exclusion

Effective CY 2027, diagnoses from chart review records not tied to a specific encounter will not count for risk adjustment.



## Major Impact

This accounts for the single largest driver of the proposed 1.78% risk score reduction.



## Revenue Risk

Retrospective chart reviews not linked to encounters place your revenue at risk.



## The Exception

Unlinked chart reviews still count for MA-to-MA switches, but not for new Original Medicare enrollees.



## CMS Visibility

CMS now sees the gap between coded data and encounter-linked records via expanded access.

# POLL: Chart Review

**Which of the following encounter-based strategies is your organization currently prioritizing to address unlinked chart review risk?**

**A. Pre-visit coder workflow**

**B. Point-of-care EMR alerts**

**C. Post-visit / concurrent coding review**

**D. We are not yet prioritizing any of these**

# The RADV and Audit Environment

## RADV Enforcement Is Expanding

CMS and OIG are signaling zero tolerance for unsupported diagnoses. The audit environment is getting materially more aggressive.



### Scope & Frequency

RADV audits are expanding in both scope and frequency across the industry.



### Evidence Standard

The bar is rising: diagnoses require clear clinical evidence, not just code presence.



### Data Access

CMS has expanded encounter data access, increasing visibility into documentation gaps.



### Proactive Action

Identify gaps with precision analytics and fix them before the audit window closes.

# Stars Changes: Why This Matters for Clinician Burden

Fewer Measures, Higher Stakes on Clinical Outcomes

11

Measures removed  
(2028–2029 Stars)

1

New behavioral measure  
(Depression Screening)

\$18.56B

Trust Fund impact  
(Stars, 2027–2036)

- **11 measures removed:** mostly operational compliance metrics where 94–97% of plans scored identically
- Removal **amplifies the weight** of clinical and experience measures
- Clinical measures now carry **more mathematical weight per measure** than at any prior point in Stars history
- **More clinical weight = more clinician burden.** Point-of-care tools are **how you reduce it**

# POLL: 2027

**What is your organization doing to prepare for the 2027 year of risk adjustment?**

**A. Adding technology**


**B. Adding coders / CDI personnel**

**C. Ramping up provider education**

**D. The same thing we did in 2026**

**E. Something Else**

# The Four HCC Coding Strategies



# Strategy 1: Pre-Visit Coder Workflow

1



TRIGGER

**Patient appointment scheduled**

A visit is booked in the EHR, the signal that starts the pre-visit workflow automatically

2



AUTOMATED

**Technology runs automated chart review**

AI scans the patient's full clinical history (diagnoses, labs, meds, notes) for HCC documentation opportunities.

3



AI OUTPUT

**HCC suspects surfaced**

Conditions flagged and ranked by clinical evidence, recapture priority, and risk score impact.

4



HUMAN REVIEW

**Coder reviews and filters**

Clinical coder removes anything not appropriate. Human judgment stays in the loop before the provider sees anything.

5



DELIVERY

**Curated suspect list delivered to provider**

A clean, prioritized list lands in the provider's EHR before the patient walks in, ready to address at the point of care.

**Encounter-linked.  
Defensible.**

# Strategy 1: Pre-Visit Coder Workflow

## The Opportunity: Strategic Impact

The pre-visit window is where technology has the biggest impact. Automation surfaces HCC suspects, which are then human-validated to provide the clinician with a curated, accurate list.

### What to Get Right

- **Human Quality Gate:**  
Technology does the heavy lift, but the coder ensures every suspect is clinically defensible.
- **Curated Focus:**  
A coder may filter three suspects down to two; the goal is accuracy over volume.
- **Actionable Data:**  
The provider receives the right information for the encounter, not an overwhelming data dump.

### Mitigating Unlinked Review Risk

#### The Direct Path:

Addressing pre-surfaced suspects during the visit ensures documentation is encounter-linked by definition.

#### Audit Defense Strategy:

This workflow proactively moves away from the risks associated with unlinked retrospective submissions.

# Strategy 2: Point of Care EMR Alerts

**< HCC Suspects** 3 to Review

AI-surfaced · Coder-reviewed · Ready for your confirmation

**C61 · HCC 80** ✓ Added

**Malignant Neoplasm of the Prostate**

HCC 80 Encounter-linked

✓ **Evidence:** Patient gender is Male and actively taking bicalutamide 50 MG Oral Tablet.

---

**Z89.511 · HCC 136** ✓ Added

**Acquired Absence of Right Leg Below Knee**

HCC 136 Claim-based

✓ **Evidence:** This code occurred on a claim from last year.

---

**196 · HCC 86** + Addd ✕

**Gangrene not elsewhere classified**

HCC 86 Uncertain

⚠ **Evidence:** Insufficient or conflicting documentation found.

---

**2**  
CONFIRMED

**0**  
PENDING

**1**  
NOT ADDED

**+1.45**  
RAF IMPACT

Submit & Close Encounter

# Strategy 2: Point of Care EMR Alerts

## The Opportunity: Real-Time Action

EMR alerts surface curated suspects during the encounter, allowing for documentation and coding at the moment of care—the gold standard for defensibility.

### What to Get Right

- **Actionable, Not Noisy:** Avoid "alert fatigue" by ensuring alerts are high-value and non-repetitive.
- **Curated Lists:** Display only pre-visit validated suspects, not a raw data dump.
- **Clinical Support:** Documentation must reflect active treatment, monitoring, or assessment.
- **Data Alignment:** Encounter and coding dates must tie up perfectly for RADV.


### Mitigating Unlinked Review Risk

**The Gold Standard:** Conditions coded during a face-to-face encounter are encounter-linked by definition.

#### **Defensibility Advantage:**

This workflow creates contemporaneous evidence that withstands RADV audits better than any retrospective method.

# Strategy 3: Post-Visit/Concurrent Coding Review



# Strategy 3: Post-Visit/Concurrent Coding Review

## The Opportunity: The Safety Net

Post-visit review catches what fell through — while the encounter is still fresh and linkable, ensuring no conditions are missed even with strong pre-visit workflows.

### What to Get Right

- **Real-time Review:** Must happen near-real-time, not months later.
- **Gap Analysis:** Identify where diagnoses fall off (providers or EDI processes).
- **Process Remediation:** Develop new processes to prevent recurrence in real-time.
- **Second-Level Review:** Implement robust checks across all vendor/internal processes.

### Mitigating Unlinked Review Risk

**The Defensible Standard:** As long as review is tied to a specific encounter and resolved while documentation is current, it remains **RADV-defensible**.

#### **The Danger Zone:**

Avoid "retrospective" review conducted months later, disconnected from the original encounter.

# POLL: Post-Visit

When your coding team conducts post-visit review, how quickly does it typically happen after the encounter closes?

A. Within 24–48 hours

B. Within the same week

C. Within the same month

D. It varies — sometimes months later

# What “Getting It Right” Actually Looks Like

**It Takes All Three Steps:** Getting it right means using all three strategies together. Everything must be linked to an encounter.

## Patterns: 10 Years & 2M+ Lives

- Single-strategy reliance leads to underperformance in risk score accuracy.
- High performance requires a coordinated pre-visit, point of care, and post-visit pipeline.
- Defensible documentation is the ultimate output for RADV audit readiness.

## Defensible Practice in Action

- Document active treatment, monitoring, or clinical management in the current year.
- Ensure encounter data and coding date line up cleanly.
- Maintain a chain of custody from suspect identification to provider submission, supported by MEAT documentation

# Integrated Action Roadmap

## Now: Before June 1

- Audit unlinked chart review usage and risk-eligible diagnosis percentages
- Model revenue impact for CY2027
- Coordinate with your payer(s) on RADV audit support to protect resources from unlinked chart reviews

## Q3 2026

- Begin encounter-based HCC documentation training
- Validate documentation and identify coding gaps
- Implement second-level coding review processes

## Q4 2026 / AEP

- Build 30-day care coordination workflows
- Develop targeted risk and quality plans for new members
- Finalize operational budgets for 2027–2028

## 2027 and Beyond

- Monitor CMS model rulemaking for future shifts
- Establish permanent encounter-based infrastructure
- Sustain consistency to maximize Stars Historical Reward

# Three Things to Prioritize Now

**1** Quantify your unlinked CRR exposure.

Risk-Eligible Diagnoses



Unlinked Diagnoses by Category



**2** Build prospective workflows — don't just plan them.



Pre-Visit



Point of Care



Post-Visit

EMR Encounter in Progress

**HCC Alert**  
HCC suspect conditions identified.  
Review and document/confirm codes.

HCC Suspect Codes


<input checked="" type="checkbox"/>	I50.32	Chronic diastolic (congestive) heart failure	Confirm
<input checked="" type="checkbox"/>	N18.31	Chronic kidney disease, stage 3a	Confirm
<input type="checkbox"/>	J44.9	Chronic obstructive pulmonary disease	Not Present

**3** Treat every chart as if it will be audited.



# Q&A

# Stop By Our VBC Exhibit Hall Booth



# More Information

## Website



[inferscience.com](https://www.inferscience.com)

## Michael Lesnik



[mlesnik@inferscience.com](mailto:mlesnik@inferscience.com)

## Subbu Ramalingam



[subbu@inferscience.com](mailto:subbu@inferscience.com)

## Sunil Nihalani



[snihalani@inferscience.com](mailto:snihalani@inferscience.com)

**Get in touch with the Inferscience team to learn more about our solutions for your CY 2027 risk adjustment strategies.**